CR20160527A - Derivados de carboxamida - Google Patents

Derivados de carboxamida

Info

Publication number
CR20160527A
CR20160527A CR20160527A CR20160527A CR20160527A CR 20160527 A CR20160527 A CR 20160527A CR 20160527 A CR20160527 A CR 20160527A CR 20160527 A CR20160527 A CR 20160527A CR 20160527 A CR20160527 A CR 20160527A
Authority
CR
Costa Rica
Prior art keywords
carboxamide derivatives
present
provides
compounds
compound
Prior art date
Application number
CR20160527A
Other languages
English (en)
Inventor
Nichola Smith
James Dale
Mahbub Ahmed
Robert Alexander Pulz
Andrew Brearley
David Andrew Sandham
Jessica Louise Taylor
Duncan Shaw
Anne-Marie D´SOUZA
Lisa Ann Rooney
Kamlesh Jagdis Bala
David Porter
Roger John Taylor
Wrigglesworth
Thomas Josef Troxler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160527(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20160527A publication Critical patent/CR20160527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención proporciona un compuesto de la fórmula (I ), o una sal farmacéut icamente aceptable del mismo: un método para la elaboración de los compuestos de la invención, y sus usos terapéut icos. La presente invención proporciona además una combinación de agentes farmacológicamente act ivos y una composición farmacéut ica.
CR20160527A 2014-05-14 2015-05-14 Derivados de carboxamida CR20160527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14168303 2014-05-14
PCT/US2015/030817 WO2015175796A1 (en) 2014-05-14 2015-05-14 Carboxamide derivatives

Publications (1)

Publication Number Publication Date
CR20160527A true CR20160527A (es) 2017-04-28

Family

ID=50735903

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160527A CR20160527A (es) 2014-05-14 2015-05-14 Derivados de carboxamida

Country Status (38)

Country Link
US (6) US9403810B2 (es)
EP (1) EP3143018B1 (es)
JP (1) JP6523338B2 (es)
KR (2) KR20230074827A (es)
CN (1) CN106661012B (es)
AP (1) AP2016009550A0 (es)
AR (1) AR100440A1 (es)
AU (1) AU2015259083B2 (es)
BR (1) BR112016026552B1 (es)
CA (1) CA2948543C (es)
CL (1) CL2016002839A1 (es)
CR (1) CR20160527A (es)
CU (1) CU24434B1 (es)
CY (1) CY1124251T1 (es)
DK (1) DK3143018T3 (es)
EA (1) EA030938B1 (es)
ES (1) ES2874882T3 (es)
HR (1) HRP20210783T1 (es)
HU (1) HUE054590T2 (es)
IL (1) IL248785B (es)
JO (1) JO3610B1 (es)
LT (1) LT3143018T (es)
MA (1) MA39983B1 (es)
MX (1) MX2016014939A (es)
MY (1) MY186598A (es)
PE (1) PE20171443A1 (es)
PH (1) PH12016502246A1 (es)
PL (1) PL3143018T3 (es)
PT (1) PT3143018T (es)
RS (1) RS61874B1 (es)
SG (1) SG11201609217UA (es)
SI (1) SI3143018T1 (es)
SV (1) SV2016005313A (es)
TN (1) TN2016000489A1 (es)
TW (2) TW201946921A (es)
UY (1) UY36124A (es)
WO (1) WO2015175796A1 (es)
ZA (1) ZA201607658B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
TW201946921A (zh) 2014-05-14 2019-12-16 瑞士商諾華公司 甲醯胺衍生物
US11078198B2 (en) * 2017-11-01 2021-08-03 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid X receptor modulators
CN108689976B (zh) * 2018-07-23 2021-12-28 陕西师范大学 5-磺基水杨酸协同二氯二茂钛催化合成4-碘代四氢吡喃衍生物的方法
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655009A1 (de) * 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US7354722B1 (en) 1999-06-11 2008-04-08 Signal Pharmaceuticals Modulators of Smurf and BMP/TGFβ signaling pathways
CN100379752C (zh) * 1999-06-11 2008-04-09 纽约州州立大学研究基金会 BMP和TGFβ信号转导途径的拮抗剂
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0312368D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
EP1667983A4 (en) 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
US7291743B2 (en) 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
MX2010001236A (es) 2007-08-02 2010-03-04 Organon Nv Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
PL2190825T3 (pl) 2007-08-22 2014-09-30 Novartis Ag Związki 5-(4-(chlorowcoalkoksy)-fenylo)-pirymidyno-2-aminowe i kompozycje jako inhibitory kinazy
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011151361A1 (en) 2010-06-03 2011-12-08 Glaxo Group Limited Novel compounds
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
US20170088546A1 (en) * 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors
MD20160121A2 (ro) 2014-05-14 2017-05-31 Pfizer Inc. Pirazolopiridine şi pirazolopirimidine
TW201946921A (zh) 2014-05-14 2019-12-16 瑞士商諾華公司 甲醯胺衍生物

Also Published As

Publication number Publication date
CY1124251T1 (el) 2022-07-22
DK3143018T3 (da) 2021-05-31
CU24434B1 (es) 2019-09-04
SV2016005313A (es) 2018-06-12
KR20230074827A (ko) 2023-05-31
CN106661012A (zh) 2017-05-10
PL3143018T3 (pl) 2021-08-30
CU20160166A7 (es) 2017-03-03
BR112016026552A8 (pt) 2021-07-06
JP2017515853A (ja) 2017-06-15
SG11201609217UA (en) 2016-12-29
US9403810B2 (en) 2016-08-02
AR100440A1 (es) 2016-10-05
LT3143018T (lt) 2021-06-10
PH12016502246B1 (en) 2017-01-09
EP3143018A1 (en) 2017-03-22
US20200268718A1 (en) 2020-08-27
KR20170003666A (ko) 2017-01-09
AU2015259083B2 (en) 2017-09-14
US20210052554A1 (en) 2021-02-25
UY36124A (es) 2016-01-08
US20190381011A1 (en) 2019-12-19
AU2015259083A1 (en) 2016-11-24
IL248785B (en) 2020-04-30
JO3610B1 (ar) 2020-08-27
SI3143018T1 (sl) 2021-08-31
MA39983B1 (fr) 2021-05-31
RS61874B1 (sr) 2021-06-30
IL248785A0 (en) 2017-01-31
CN106661012B (zh) 2019-12-20
US20230301970A1 (en) 2023-09-28
CL2016002839A1 (es) 2017-01-27
US10195181B2 (en) 2019-02-05
CA2948543A1 (en) 2015-11-19
EA030938B1 (ru) 2018-10-31
TW201946921A (zh) 2019-12-16
PE20171443A1 (es) 2017-09-29
JP6523338B2 (ja) 2019-05-29
ZA201607658B (en) 2017-09-27
PT3143018T (pt) 2021-06-01
HUE054590T2 (hu) 2021-09-28
WO2015175796A1 (en) 2015-11-19
BR112016026552B1 (pt) 2023-02-14
TW201623296A (zh) 2016-07-01
US20150329529A1 (en) 2015-11-19
HRP20210783T1 (hr) 2021-06-25
CA2948543C (en) 2022-08-16
US11672782B2 (en) 2023-06-13
MA39983A (fr) 2017-03-22
TN2016000489A1 (en) 2018-04-04
ES2874882T3 (es) 2021-11-05
EP3143018B1 (en) 2021-03-10
NZ725918A (en) 2023-09-29
PH12016502246A1 (en) 2017-01-09
TWI714528B (zh) 2021-01-01
US20170014388A1 (en) 2017-01-19
MY186598A (en) 2021-07-29
EA201692300A1 (ru) 2017-04-28
AP2016009550A0 (en) 2016-11-30
KR102534033B1 (ko) 2023-05-19
BR112016026552A2 (pt) 2017-08-15
MX2016014939A (es) 2017-02-28

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CR20160527A (es) Derivados de carboxamida
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR103680A1 (es) Inhibidores selectivos de bace1
UY36123A (es) Derivados de carboxamida
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
UY36084A (es) Activadores de herg policíclicos
CU20160170A7 (es) Derivados de carboxamida
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos